Modopar L.P. 125 (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system it is converted to dopamine, compensating for the loss of dopaminergic neurons characteristic of Parkinsonian disorders. Benserazide prevents peripheral conversion, ensuring more levodopa reaches the brain.

The appropriate dose of Modopar L.P. 125 is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage adjustments are made gradually to balance symptom control with potential side effects, and patients should follow their doctor's specific instructions.

The safety of Modopar L.P. 125 in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Modopar L.P. 125 combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with other combination products (e.g., levodopa/carbidopa), the clinical efficacy is similar, but individual tolerability and side‑effect profiles may differ, influencing the choice of therapy.

Store Modopar L.P. 125 tablets at ambient temperature, below 25 °C, in the original container. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

Modopar L.P. 125 is taken orally with a glass of water, usually with meals to lessen gastrointestinal upset. The tablet should be swallowed whole and not split, chewed, or crushed unless specifically instructed by a healthcare professional.

Serious risks include the development of severe dyskinesia, hallucinations or psychosis, and cardiovascular events such as marked hypotension or arrhythmias. Patients should be monitored closely for these reactions, and any concerning symptoms should prompt immediate medical evaluation.

Modopar L.P. 125 is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the tablet. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, unless directed by a specialist.